TERN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.304

+26.63%

-0.303

+16.67%

-0.317

+21.8%

Estimates Revision

The market is revising No Change the revenue expectations for Terns Pharmaceuticals, Inc. (TERN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 502.88%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+502.88%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast TERN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 25.00 USD with a low forecast of 15.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

0 Sell

Strong Buy

Current: 44.010

Low

15.00

Averages

25.00

High

35.00

Current: 44.010

Low

15.00

Averages

25.00

High

35.00

Citizens

Outperform

maintain

$35 -> $57

2025-12-11

New

Reason

Citizens

Price Target

$35 -> $57

2025-12-11

New

maintain

Outperform

Reason

Citizens raised the firm's price target on Terns Pharmaceuticals to $57 from $35 and keeps an Outperform rating on the shares. Terns' interim Phase 1 CARDINAL ASH update highlighted the best-in-class profile of TERN-701, the analyst tells investors in a research note. Key additional data points were the high deep molecular response rate, setting it up well in 1L, and the strong activity post asciminib and ponatinib, which is very positive in 2L, Citizens says.

Truist

Buy

maintain

$35 -> $56

2025-12-09

Reason

Truist

Price Target

$35 -> $56

2025-12-09

maintain

Buy

Reason

Truist raised the firm's price target on Terns Pharmaceuticals to $56 from $35 and keeps a Buy rating on the shares. The company reported updated Phase 1 CARDINAL data evaluating allosteric TKI TERN-701 in 38 patients, and the firm is reiterating its conviction in TERN-701 and sees increased potential in frontline use, especially with the groundbreaking efficacy shown, the analyst tells investors in a research note. Truist adds that it believes that the strong safety profile with a convenient daily oral dosing adds to the differentiated profile for the drug.

BMO Capital

Outperform

maintain

$35 -> $54

2025-12-09

Reason

BMO Capital

Price Target

$35 -> $54

2025-12-09

maintain

Outperform

Reason

BMO Capital raised the firm's price target on Terns Pharmaceuticals to $54 from $35 and keeps an Outperform rating on the shares. Full CARDINAL data and management call increases the firm's confidence in TERN-701 again, and with TERN-701 clearly showing a differentiated tolerabiltiy and efficacy profile vs. existing allosteric inhibitors, the firm is increasing its long-term peak adjusted sales again to $3.4B, the analyst tells investors in a research note. BMO adds that its positive view on the stock is buoyed by a small molecule platform, which the firm believes can deliver differentiated assets that have been clinically validated in several indications.

Oppenheimer

Outperform

upgrade

$28 -> $58

2025-12-09

Reason

Oppenheimer

Price Target

$28 -> $58

2025-12-09

upgrade

Outperform

Reason

Oppenheimer raised the firm's price target on Terns Pharmaceuticals to $58 from $28 and keeps an Outperform rating on the shares. The firm notes the company reported detailed results from the ongoing CARDINAL trial of TERN-701 in CML. While Terns' shares rose 250% following the release of ASH abstract in early November, the detailed results at ASH provided additional clarity on the emerging profile for TERN-701, as overall 6-month MMR rate was maintained at a 74% across all dose cohorts; an even higher 6-month MMR rate of 80% Ammon patients dosed at 320mg QD or higher; and favorable tolerability profile. Oppenheimer thinks today's update supports a best-in-class profile for TERN-701 in the CML market and supports both first line and second line and beyond opportunities.

Barclays

Etzer Darout

Overweight

maintain

$36 -> $56

2025-12-09

Reason

Barclays

Etzer Darout

Price Target

$36 -> $56

2025-12-09

maintain

Overweight

Reason

Barclays analyst Etzer Darout raised the firm's price target on Terns Pharmaceuticals to $56 from $36 and keeps an Overweight rating on the shares. The TERN-701 update supports the stock's valuation update and shows a potential best-in-class" efficacy and safety profile, the analyst tells investors in a research note. The firm says treatment duration is still an important lever that longer term follow up will help refine.

H.C. Wainwright

Buy

maintain

$20 -> $60

2025-12-09

Reason

H.C. Wainwright

Price Target

$20 -> $60

2025-12-09

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Terns Pharmaceuticals to $60 from $20 and keeps a Buy rating on the shares. The firm says the updated Phase 1 CARDINAL data for TERN-701 reinforced that its emerging efficacy profile materially exceeds what is achievable with current BCR ABL1 inhibitors.

Valuation Metrics

The current forward P/E ratio for Terns Pharmaceuticals Inc (TERN.O) is -34.35, compared to its 5-year average forward P/E of -5.00. For a more detailed relative valuation and DCF analysis to assess Terns Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.00

Current PE

-34.35

Overvalued PE

-1.43

Undervalued PE

-8.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.09

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.87

Undervalued EV/EBITDA

-6.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.43

Current PS

0.00

Overvalued PS

55.57

Undervalued PS

-34.72

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 5858.69% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 5858.69% over the last month.

Sold

Bought

TERN News & Events

Events Timeline

No data

News

8.5

12-11Globenewswire

Terns Pharmaceuticals Closes $747.5 Million Public Offering of 18.69 Million Shares

8.5

12-10Globenewswire

Terns Pharmaceuticals Prices Upsized Offering of 16.25 Million Shares at $40 Each, Raising $650 Million

9.0

12-09Barron's

Cancer Research Boosts Confidence in These Small Biotech Companies

People Also Watch

Frequently Asked Questions

What is Terns Pharmaceuticals Inc (TERN) stock price today?

The current price of TERN is 44.01 USD — it has decreased -2.2 % in the last trading day.

What is Terns Pharmaceuticals Inc (TERN)'s business?

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

What is the price predicton of TERN Stock?

What is Terns Pharmaceuticals Inc (TERN)'s revenue for the last quarter?

Terns Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Terns Pharmaceuticals Inc (TERN)'s earnings per share (EPS) for the last quarter?

Terns Pharmaceuticals Inc. EPS for the last quarter amounts to -0.27 USD, decreased -3.57 % YoY.

What changes have occurred in the market's expectations for Terns Pharmaceuticals Inc (TERN)'s fundamentals?

How many employees does Terns Pharmaceuticals Inc (TERN). have?

Terns Pharmaceuticals Inc (TERN) has 59 emplpoyees as of December 16 2025.

What is Terns Pharmaceuticals Inc (TERN) market cap?

Today TERN has the market capitalization of 4.79B USD.